| Literature DB >> 25479769 |
Uwe Konerding1, Sylvia G Elkhuizen2, Raquel Faubel3, Paul Forte4, Tomi Malmström5, Elpida Pavi6, M F Bas Janssen7.
Abstract
BACKGROUND: Most previous studies concerning the validity of the EQ-5D-3L items refer to applications of only a single language version of the EQ-5D-3L in only one country. Therefore, there is little information concerning the extent to which the results can be generalised across different language versions and/or different countries. Here the validity of the EQ-5D-3L items is investigated for six different language versions in six different countries.Entities:
Mesh:
Year: 2014 PMID: 25479769 PMCID: PMC4263046 DOI: 10.1186/s12955-014-0181-5
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
General information about the sample
|
|
|
|
|
| |
|---|---|---|---|---|---|
| England | 3343 | 475 | 313 | 436 | 289 |
| Finland | 436 | 183 | 183 | 177 | 177 |
| Germany | 462 | 286 | 282 | 259 | 255 |
| Greece | 600 | 179 | 179 | 165 | 165 |
| The Netherlands | 779 | 400 | 387 | 364 | 354 |
| Spain | 625 | 115 | 115 | 101 | 101 |
| All countries | 6245 | 1638 | 1459 | 1502 | 1341 |
aParticipants who answered at least two of the three socio-demographic questions, at least four of the five questions concerning secondary complications, and at least four of the five EQ-5D-3L questions.
Distributions of the investigated variables
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Socio-demographic features | |||||||
| Age (p < 0.001)b | |||||||
| Mean | 63.2 | 64.2 | 66.1 | 66.4 | 65.9 | 68.5 | 65.4 |
| SD | 12.8 | 9.5 | 11.4 | 10.7 | 10.3 | 11.6 | 11.2 |
| Minimum | 28 | 34 | 21 | 30 | 38 | 30 | 21 |
| Maximum | 90 | 98 | 92 | 89 | 89 | 92 | 98 |
| <55 | 69 (24.0%) | 25 (14.4%) | 38 (15.0%) | 20 (12.1%) | 45 (12.8%) | 12 (11.9%) | 209 (15.7%) |
| 55-64 | 77 (26.8%) | 60 (34.5%) | 62 (24.4%) | 48 (29.1%) | 111 (31.6%) | 17 (16.8%) | 375 (28.2%) |
| 65-74 | 83 (28.9%) | 68 (39.1%) | 93 (36.6%) | 52 (31.5%) | 118 (33.6%) | 38 (37.6%) | 452 (33.9%) |
| >74 | 58 (20.2%) | 21 (12.1%) | 61 (24.0%) | 45 (27.3%) | 77 (21.9%) | 34 (33.7%) | 296 (22.2%) |
| Gender (not significant)c | |||||||
| Female | 114 (40.1%) | 66 (37.9%) | 127 (50.0%) | 71 (43.0%) | 147 (42.6%) | 45 (45.0%) | 570 (43.1%) |
| Male | 170 (59.9%) | 108 (62.1%) | 127 (50.0%) | 94 (57.0%) | 198 (57.4%) | 55 (55.0%) | 752 (56.9%) |
| Education (p < 0.001)c | |||||||
| Low | 164 (62.8%) | 70 (42.9%) | 87 (35.4%) | 116 (73.4%) | 84 (24.7%) | 64 (68.1%) | 585 (46.4%) |
| High | 97 (37.2%) | 93 (57.1%) | 159 (64.6%) | 42 (26.6%) | 256 (75.3%) | 30 (31.9%) | 677 (53.6%) |
| Secondary complications | |||||||
| Stroke (p < 0.05)c | |||||||
| No | 263 (91.0%) | 168 (94.9%) | 228 (89.4%) | 152 (92.1%) | 337 (95.7%) | 95 (95.0%) | 1243 (92.9%) |
| Yes | 26 (9.0%) | 9 (5.1%) | 27 (10.6%) | 13 (7.9%) | 15 (4.3%) | 5 (5.0%) | 95 (7.1%) |
| Heart (p < 0.01)d | |||||||
| No problems | 215 (76.0%) | 127 (78.4%) | 177 (76.6%) | 109 (69.0%) | 286 (84.4%) | 82 (82.8%) | 996 (78.3%) |
| Problems, no attack | 40 (14.1%) | 20 (12.3%) | 32 (13.9%) | 28 (17.7%) | 30 (8.8%) | 8 (8.1%) | 158 (12.4%) |
| Heart attack | 28 (9.9%) | 15 (9.3%) | 22 (9.5%) | 21 (13.3%) | 23 (6.8%) | 9 (9.1%) | 118 (9.3%) |
| Kidney (not significant)c | |||||||
| No kidney failure | 276 (99.6%) | 173 (100.0%) | 243 (99.2%) | 158 (99.4%) | 348 (100.0%) | 100 (100.0%) | 1298 (99.7%) |
| Kidney failure | 1 (0.4%) | 0 (0.0%) | 2 (0.8%) | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) | 4 (0.3%) |
| Lower extremities (p < 0.001)d | |||||||
| No problems | 230 (81.3%) | 149 (86.1%) | 185 (73.4%) | 144 (87.8%) | 318 (93.8%) | 83 (83.8%) | 1109 (84.7%) |
| Moderate problems | 43 (15.2%) | 23 (13.3%) | 63 (25.0%) | 18 (11.0%) | 21 (6.2%) | 15 (15.2%) | 183 (14.0%) |
| Amputations | 10 (3.5%) | 1 (0.6%) | 4 (1.6%) | 2 (1.2%) | 0 (0.0%) | 1 (1.0%) | 18 (1.4%) |
| Eyes (p < 0.001)d | |||||||
| No problems | 209 (73.6%) | 155 (89.1%) | 202 (79.5%) | 134 (81.7%) | 315 (91.0%) | 73 (73.0%) | 1088 (82.3%) |
| Moderate problems | 74 (26.1%) | 19 (10.9%) | 52 (20.5%) | 29 (17.7%) | 31 (9.0%) | 26 (26.0%) | 231 (17.5%) |
| Blind | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) | 1 (0.6%) | 0 (0.0%) | 1 (1.0%) | 3 (0.2%) |
| EQ-5D-3L items | |||||||
| Mobility (p < 0.001)d | |||||||
| No problems | 142 (49.3%) | 104 (58.8%) | 167 (65.5%) | 84 (50.9%) | 242 (68.8%) | 58 (58.0%) | 797 (59.6%) |
| Some problems | 143 (49.7%) | 73 (41.2%) | 88 (34.5%) | 81 (49.1%) | 110 (31.3%) | 41 (41.0%) | 536 (40.1%) |
| Confined to bed | 3 (1.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.0%) | 4 (0.3%) |
| Self-care (p < 0.001)d | |||||||
| No problems | 212 (73.4%) | 157 (88.7%) | 223 (87.5%) | 149 (90.3%) | 330 (94.8%) | 83 (83.0%) | 1154 (86.5%) |
| Some problems | 67 (23.2%) | 20 (11.3%) | 30 (11.8%) | 13 (7.9%) | 15 (4.3%) | 15 (15.0%) | 160 (12.0%) |
| Unable | 10 (3.5%) | 0 (0.0%) | 2 (0.8%) | 3 (1.8%) | 3 (0.9%) | 2 (2.0%) | 20 (1.5%) |
| Usual activities (p < 0.001)d | |||||||
| No problems | 158 (54.9%) | 129 (72.9%) | 182 (71.7%) | 110 (67.1%) | 272 (77.3%) | 71 (70.3%) | 922 (69.0%) |
| Some problems | 103 (35.8%) | 45 (25.4%) | 67 (26.4%) | 47 (28.7%) | 77 (21.9%) | 25 (24.8%) | 364 (27.2%) |
| Unable | 27 (9.4%) | 3 (1.7%) | 5 (2.0%) | 7 (4.3%) | 3 (0.9%) | 5 (5.0%) | 50 (3.7%) |
| Pain/discomfort (p < 0.001)d | |||||||
| No | 120 (41.5%) | 77 (44.0%) | 76 (30.0%) | 65 (39.6%) | 200 (56.8%) | 43 (42.6%) | 581 (43.6%) |
| Moderate | 129 (44.6%) | 93 (53.1%) | 158 (62.5%) | 92 (56.1%) | 141 (40.1%) | 48 (47.5%) | 661 (49.6%) |
| Extreme | 40 (13.8%) | 5 (2.9%) | 19 (7.5%) | 7 (4.3%) | 11 (3.1%) | 10 (9.9%) | 92 (6.9%) |
| Anxiety/depression (p < 0.001)d | |||||||
| Not | 156 (54.9%) | 156 (88.6%) | 175 (70.3%) | 34 (20.9%) | 302 (85.6%) | 56 (56.0%) | 879 (66.3%) |
| Moderately | 108 (38.0%) | 17 (9.7%) | 67 (26.9%) | 97 (59.5%) | 50 (14.2%) | 40 (40.0%) | 379 (28.6%) |
| Extremely | 20 (7.0%) | 3 (1.7%) | 7 (2.8%) | 32 (19.6%) | 1 (0.3%) | 1 (0.3%) | 67 (5.1%) |
aDue to missing values the numbers of cases evaluated for each variable are mostly lower than the sample sizes. Percentages refer to the ‘within country’ distributions of the variables (columns).
bTest for country differences performed with multiple linear regression with ‘country’ as dummy coded independent variable.
cTest for country differences performed with Pearson’s chi-square test.
dTest for country differences performed with Kruskal-Wallis test.
Model fits for data from all six study countries
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Age | 0.13; 0.15 | 0.14; n.d.b | 0.10; 0.12 | 0.07; 0.09 | 0.26; 0.27 |
| Gender | 0.07; 0.08* | 0.10; 0.11 | 0.07; 0.08 | 0.09; 0.10 | 0.27; 0.27 |
| Education | 0.04; 0.04 | 0.10; 0.10 | 0.06; 0.06 | 0.05; 0.06 | 0.27; 0.27 |
| Previous stroke | 0.07; n.d.b | 0.13; 0.13 | 0.11; n.d.b | 0.05; n.d.b | 0.27; 0.27 |
| Problems with heart | 0.08; 0.09 | 0.13; 0.14 | 0.09; 0.09 | 0.06; 0.07* | 0.26; 0.26 |
| Problems with lower extremities | 0.16; 0.17 | 0.19; 0.19 | 0.14; 0.14 | 0.12; 0.13 | 0.29; 0.29 |
| Problems with eyes | 0.09; 0.09 | 0.15; 0.16* | 0.08; 0.09 | 0.08; 0.08 | 0.27; 0.28 |
aFirst number in each cell is Nagelkerke’s R2 for the model without interaction terms, the second number is Nagelkerke’s R2 for the model with interaction terms. Asterisks behind the second number symbolise the results of the test as to whether the second model explains the dependent variable significantly better than the first. * = ‘p < 0.05’.
bn.d. means not determinable.
Model fits without Spanish data
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Age | 0.14; 0.15 | 0.14; 0.16 | 0.10; 0.12 | 0.07; 0.09 | 0.27; 0.29 |
| Gender | 0.07; 0.07 | 0.11; 0.11 | 0.07; 0.07 | 0.08; 0.09 | 0.28; 0.29 |
| Education | 0.04; 0.05 | 0.10; 0.11 | 0.06; 0.06 | 0.06; 0.07* | 0.28; 0.29 |
| Previous stroke | 0.07; 0.07 | 0.13; 0.14 | 0.10; 0.11 | 0.06; 0.06 | 0.28; 0.28 |
| Problems with heart | 0.09; 0.10 | 0.13; 0.15 | 0.09; 0.10 | 0.07; 0.08 | 0.28; 0.28 |
| Problems with lower extremities | 0.15; 0.16 | 0.19; 0.19 | 0.14; 0.15 | 0.12; 0.13 | 0.30; 0.30 |
| Problems with eyes | 0.09; 0.10 | 0.17; 0.18 | 0.10; 0.11 | 0.09; 0.09 | 0.29; 0.29 |
aFirst number in each cell is Nagelkerke’s R2 for the model without interaction terms, the second number is Nagelkerke’s R2 for the model with interaction terms. Asterisks behind the second number symbolise the results of the test as to whether the second model explains the dependent variable significantly better than the first. * = ‘p < 0.05’.
Regression coefficients for models without interaction terms, Spanish data excluded
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Age | |||||
| <55 (reference) | |||||
| 55-64 | 0.45* | 0.19 | 0.24 | 0.34 | 0.11 |
| 0.05; 0.85 | −0.42; 0.80 | −0.18; 0.65 | −0.02; 0.69 | −0.31; 0.52 | |
| 65-74 | 0.72*** | 0.43 | 0.32 | 0.35 | 0.03 |
| 0.33; 1.11 | −0.15; 1.01 | −0.08; 0.72 | −0.00; 0.69 | −0.38; 0.43 | |
| >74 | 1.82*** | 1.38*** | 1.30*** | 0.92*** | −0.14 |
| 1.40; 2.25 | 0.80; 1.96 | 0.88; 1.73 | 0.53; 1.31 | −0.59; 0.30 | |
| Male gender | −0.61*** | −0.46** | −0.61*** | −0.68*** | −0.46** |
| −0.85; −0.38 | −0.80; −0.11 | −0.86; −0.36 | −0.91; −0.44 | −0.73; −0.18 | |
| Higher education | −0.33* | −0.35 | −0.36** | −0.33* | −0.03 |
| −0.59; −0.08 | −0.73; 0.03 | −0.63; −0.09 | −0.59; −0.08 | −0.33; 0.27 | |
| Previous stroke | 1.28*** | 1.41*** | 1.72*** | 0.65** | 0.87*** |
| 0.81; 1.75 | 0.92; 1.90 | 1.25; 2.20 | 0.17; 1.14 | 0.40; 1.35 | |
| Problems with heart | 0.98*** | 0.86*** | 0.89*** | 0.68*** | 0.45** |
| 0.69; 1.27 | 0.47; 1.24 | 0.60; 1.18 | 0.38; 0.98 | 0.13; 0.77 | |
| Problems with lower extremities | 1.81*** | 1.67*** | 1.62*** | 1.56*** | 0.95*** |
| 1.44; 2.18 | 1.27; 2.06 | 1.27; 1.96 | 1.14; 1.99 | 0.59; 1.31 | |
| Problems with eyes | 1.17*** | 1.46*** | 1.72*** | 0.99*** | 0.76*** |
| 0.85; 1.49 | 1.09; 1.84 | 1.25; 2.20 | 0.64; 1.34 | 0.43; 1.10 |
aFirst entry in the cell is the regression coefficient, i.e. the logarithm of the odds ratio. The asterisks behind this entry mark the results of the significance test for deviation from zero, with * = ‘p < 0.05’, **=’p < 0.01’, ***=’p < 0.001’. The numbers in the second row of each cell are the boundaries of the 95%-interval of confidence for the regression coefficient.